Cosunter(SZ:300436) Xin Lang Cai Jing·2025-10-15 01:56Group 1 - The core viewpoint of the news is that Guangshentang's stock price increased by 5.54%, reaching 107.87 CNY per share, with a trading volume of 317 million CNY and a turnover rate of 2.19%, resulting in a total market capitalization of 17.18 billion CNY [1] - Guangshentang Pharmaceutical Co., Ltd. is located in Fuzhou, Fujian Province, and was established on June 28, 2001, with its listing date on April 22, 2015. The company specializes in the research, production, and sales of nucleoside antiviral drugs for hepatitis B [1] - The main business revenue composition of Guangshentang is 98.54% from liver and gallbladder disease drugs and 1.46% from other supplementary products [1] Group 2 - Among the top ten circulating shareholders of Guangshentang, a fund under China Europe Fund, specifically the China Europe Medical Health Mixed A (003095), increased its holdings by 393,100 shares in the second quarter, holding a total of 1.8447 million shares, which accounts for 1.35% of the circulating shares [2] - The estimated floating profit for the fund from this investment is approximately 10.44 million CNY [2] - The China Europe Medical Health Mixed A fund was established on September 29, 2016, with a current scale of 15.638 billion CNY, and has achieved a year-to-date return of 19.84% [2]